Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities
Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM
Published in BMJ Open Gastroenterology
Methodology
Prospective observational study of polyenylphosphatidylcholine added to standard care in patients with NAFLD and cardiometabolic comorbidities
Key Findings
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Conclusions
Phosphatidylcholine may support improvement of hepatic steatosis alongside standard care
Limitations
Open-label, no control group, manufacturer sponsored, ultrasound endpoints
Supplements Studied
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Outcomes Measured
Ultrasound-assessed steatosis and liver enzymes improved over 24 weeks of phosphatidylcholine treatment
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.